Uwe Trefzer

10.7k total citations · 1 hit paper
78 papers, 4.5k citations indexed

About

Uwe Trefzer is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Uwe Trefzer has authored 78 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 42 papers in Oncology and 28 papers in Immunology. Recurrent topics in Uwe Trefzer's work include Immunotherapy and Immune Responses (23 papers), Melanoma and MAPK Pathways (22 papers) and CAR-T cell therapy research (20 papers). Uwe Trefzer is often cited by papers focused on Immunotherapy and Immune Responses (23 papers), Melanoma and MAPK Pathways (22 papers) and CAR-T cell therapy research (20 papers). Uwe Trefzer collaborates with scholars based in Germany, United States and Switzerland. Uwe Trefzer's co-authors include Dirk Schadendorf, Wolfram Sterry, Peter Hersey, Claus Garbe, Caroline Robert, Reinhard Dummer, Peter Mohr, Peter Walden, Jessica C. Hassel and John M. Kirkwood and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Uwe Trefzer

77 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

2012 1.1k citations Claus Garbe, Jessica C. Hassel et al. profile →

Peers

Countries citing papers authored by Uwe Trefzer

Since Specialization

Citations

This map shows the geographic impact of Uwe Trefzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uwe Trefzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uwe Trefzer more than expected).

Fields of papers citing papers by Uwe Trefzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uwe Trefzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uwe Trefzer. The network helps show where Uwe Trefzer may publish in the future.

Co-authorship network of co-authors of Uwe Trefzer

This figure shows the co-authorship network connecting the top 25 collaborators of Uwe Trefzer. A scholar is included among the top collaborators of Uwe Trefzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uwe Trefzer. Uwe Trefzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients 2019 ·Cancer Immunology Immunotherapy ·Benjamin Weide, Thomas Eigentler, Chiara Catania, Paolo A. Ascierto, Stefano Cascinu, Jürgen C. Becker, Axel Hauschild, Antonella Romanini, Riccardo Danielli, Reinhard Dummer, Uwe Trefzer, Giuliano Elia, Dario Neri, Claus Garbe	41
2	Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study 2017 ·Journal of the European Academy of Dermatology and Venereology ·John T. Lear, Michael R. Migden, Karl D. Lewis, Anne Lynn S. Chang, Alexander Guminski, Ralf Gutzmer, Luc Dirix, P. Combemale, Alexander Stratigos, Ruth Plummer, Henry Castro, Tingting Yi, Manisha Mone, (unknown), Uwe Trefzer, Martin Kaatz, Carmen Loquai, Ragini R. Kudchadkar, Dalila Sellami, Reinhard Dummer	137
3	Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study 2014 ·Journal for ImmunoTherapy of Cancer ·Uwe Trefzer, Ralf Gutzmer, Tabea Wilhelm, Florian Schenck, Katharina C. Kähler, (unknown), Klaus Witthohn, Hans Lentzen, Peter Mohr	7
4	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma 2013 ·Journal of Clinical Oncology ·Paolo A. Ascierto, David R. Minor, Antoni Ribas, Célèste Lebbé, Anne O’Hagan, Niki Arya, Mary Guckert, Dirk Schadendorf, Richard Kefford, Jean‐Jacques Grob, Omid Hamid, Ravi K. Amaravadi, Ester Simeone, Tabea Wilhelm, Kevin B. Kim, Georgina V. Long, Anne-Marie Martin, Jolly Mazumdar, Vicki Goodman, Uwe Trefzer	338
5	Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients 2011 ·The Journal of Dermatology ·Maja A. Hofmann, B Schicke, (unknown), (unknown), (unknown), Ingeborg Küchler, Christiane Voit, Uwe Trefzer	13
6	Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial 2011 ·Annals of Oncology ·Friederike Egberts, Ralf Gutzmer, Selma Ugurel, Jürgen C. Becker, Uwe Trefzer, A. Degen, Florian Schenck, (unknown), Tabea Wilhelm, Jessica C. Hassel, Dirk Schadendorf, Elisabeth Livingstone, Cornelia Mauch, Claus Garbe, Carola Berking, Knuth Rass, Peter Mohr, Katharina C. Kaehler, Michael Weichenthal, Axel Hauschild	26
7	Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma 2011 ·Journal of Investigative Dermatology ·David Schrama, Wiebke K. Peitsch, Marc Zapatka, Hermann Kneitz, Roland Houben, (unknown), Sebastian Haferkamp, Patrick S. Moore, Masahiro Shuda, John F. Thompson, Uwe Trefzer, Claudia Pföhler, Richard A. Scolyer, Jürgen C. Becker	122
8	Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma 2009 ·Melanoma Research ·Maja A. Hofmann, (unknown), Andreas Fritsche, (unknown), B Schicke, Ingeborg Küchler, Christiane Voit, Uwe Trefzer	20
9	Proteome Serological Determination of Tumor-Associated Antigens in Melanoma 2009 ·PLoS ONE ·(unknown), Uwe Trefzer, Wolfram Sterry, Peter Walden	33
10	The Tumor Suppressive Reagent Taurolidine Inhibits Growth of Malignant Melanoma—a Mouse Model 2007 ·Journal of Surgical Research ·Chris Braumann, Christoph A. Jacobi, Stephan Rogalla, Charalambos Menenakos, (unknown), Uwe Trefzer, Maja A. Hofmann	17
11	Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial 2007 ·Melanoma Research ·Albrecht Reichle, Thomas Vogt, Brigitte Coras, (unknown), (unknown), Uwe Trefzer, Erwin Schultz, Anna Berand, E.‐B. Bröcker, Michael Landthaler, Reinhard Andreesen	33
12	The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma 2006 ·BMC Cancer ·Uwe Trefzer, (unknown), Gunda Herberth, Maja A. Hofmann, Felix Kiecker, Yajun Guo, Wolfram Sterry	10
13	Loss of Proapoptotic Bcl-2-Related Multidomain Proteins in Primary Melanomas Is Associated with Poor Prognosis 2006 ·Journal of Investigative Dermatology ·Lothar F. Fecker, Christoph C. Geilen, Georgi Tchernev, Uwe Trefzer, Chalid Assaf, (unknown), Constanze Schwarz, Peter T. Daniel, Jürgen Eberle	55
14	Absence of Classical MAP Kinase Pathway Signalling in Merkel Cell Carcinoma 2006 ·Journal of Investigative Dermatology ·Roland Houben, Barbara Michel, Claudia S. Vetter‐Kauczok, Claudia Pföhler, (unknown), Manfred Wolter, J. Helen Leonard, Uwe Trefzer, Selma Ugurel, David Schrama, Juergen C. Becker	46
15	Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy 2006 ·Melanoma Research ·Uwe Trefzer, Maja A. Hofmann, (unknown), Yajun Guo, Heike Audring, Giulio C. Spagnoli, Wolfram Sterry	24
16	Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results 2005 ·Vaccine ·Uwe Trefzer, Gunda Herberth, (unknown), (unknown), (unknown), (unknown), Katrin Sparbier, Wolfram Sterry, Peter Walden	61
17	Antitumour activity of paclitaxel and interferon‐alpha in a case of metastatic eccrine porocarcinoma 2004 ·Journal of the European Academy of Dermatology and Venereology ·Jan Gutermuth, Heike Audring, Christiane Voit, Uwe Trefzer, N. Haas	30
18	SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions 2000 ·Archives of Dermatological Research ·Uwe Trefzer, (unknown), (unknown), Heike Audring, Gunda Herberth, (unknown), (unknown), (unknown), Shuguang Wu, Jing Ma, Yanjun Liu, HUIQUN WANG, Wolfram Sterry, Yajun Guo	33
19	Gene therapy of cancer 1998 ·Immunology Today ·Farzin Farzaneh, Uwe Trefzer, Wolfram Sterry, Peter Walden	15
20	A Phase I Trial with a Hybrid Cell Vaccine in Patients with Metastatic Melanoma 1998 ·Advances in experimental medicine and biology ·Uwe Trefzer, (unknown), (unknown), (unknown), Heike Audring, H. Winter, Yugang Guo, Wolfram Sterry, Peter Walden	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact